Vielversprechende Langzeitergebnisse zum Einsatz von Anastrozol zur Prävention von Brustkrebs bei postmenopausalen Hochrisikopatientinnen-Reference-Cited by-同舟云学术

Vielversprechende Langzeitergebnisse zum Einsatz von Anastrozol zur Prävention von Brustkrebs bei postmenopausalen Hochrisikopatientinnen

Published:2020-06-23 Issue:10 Volume:196 Page:954-955
ISSN:0179-7158
Container-title:Strahlentherapie und Onkologie
language:de
Short-container-title:Strahlenther Onkol

Author:

Trabitzsch Josephin,Schenke Hendrik

Funder

Universitätsklinikum Schleswig-Holstein - Campus Kiel

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Radiology Nuclear Medicine and imaging

Link

https://link.springer.com/content/pdf/10.1007/s00066-020-01650-8.pdf

Reference8 articles.

1. Cuzick J, Sestak I, Cawthorn S et al (2015) Tamoxifen for prevention of breast cancer. Extended long-term follow-up of the IBIS‑I breast cancer prevention trial. Lancet Oncol 16:67–75. https://doi.org/10.1016/S1470-2045(14)71171-4

2. Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II). An international, double-blind, randomised placebo-controlled trial. Lancet 383:1041–1048. https://doi.org/10.1016/S0140-6736(13)62292-8

3. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

4. NICE (2013) Familial breast cancer. Classification, care and managing breast cancer and related risks in people with a family history of breast cancer

5. Owens DK, Davidson KW, Krist AH et al (2019) Medication use to reduce risk of breast cancer. US preventive services task force recommendation statement. JAMA 322:857–867. https://doi.org/10.1001/jama.2019.11885